New hope for advanced prostate cancer: experimental drug GDC-1261 enters trials

NCT ID NCT07567846

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must already be on hormone therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Austin Hospital
RECRUITING

Heidelberg, Victoria, 3084, Australia
Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258-4566, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
St Vincent's Hospital Sydney
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
The Royal Marsden in Sutton, Surrey - Downs Rd
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.